***(a)***



*p <0.0001*



*p <0.0001*

Over 5 yrs of age at ART initiation

***(b)***



*p <0.0001*

Excluding early losses to follow-up at 0.001 yrs

***(c)***



*p <0.0001*

Supplementary Fig. S1. Retention in care to 5 years on treatment by a) treatment initiation period, stratified by age at ART initiation, b) baseline regimen excluding early losses to follow-up at 0.001 years and c) viral suppression in children with a recent viral load test receiving 6 months or more of ART (p = Log-rank test).  
A3E, Abacavir Lamivudine Efavirenz; A3L, Abacavir Lamivudine Lopinavir; ART, Antiretroviral Therapy; LTFU, Losses to Follow-Up; S3E, Stavudine Lamivudine Efavirenz; S3L, Stavudine Lamivudine Lopinavir